Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Protagonist (Nasdaq: PTGX) is one of a handful of Bay Area drug developers ready to ask the Food and Drug Administration to ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional Office in San Francisco, a major HIV drug maker ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

says Marcus Wilson, Gilead Senior Director, U.S. Public Affairs, HIV Advocacy. "It determines the quality of care that people receive; whether they feel safe seeking care and, ultimately ...